CIK 0001847367 · <br>Emerging growth company
ALUMIS INC.
Sign in to watch- Ticker
- ALMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 650-231-6625
- Business address
- 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- FL2021-001, Inc.
- Open-market buys, last 90 days
- $10,726,255
- in 1 filing
- Open-market sales, last 90 days
- $1,037,650
- in 7 filings
Net +$9,688,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- AKKARAJU SRINIVAS +$9.7M Director sold 4% of stake
- Schroer John R. −$5K Chief Financial Officer sold 3% of stake
- Hardiman Roy C. −$4K Chief Business & Strategy Ofcr sold <1% of stake
- Goldstein David M −$4K Chief Scientific Officer sold 2% of stake
- Bradley Mark Christopher −$4K Chief Development Officer sold 1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-01 | Foresite Capital Management VI LLC 10% owner | Other acquisition | +1,123,337 | 1,123,337 | ||
| 2026-04-01 | Foresite Capital Management VI LLC 10% owner | Other disposition | −1,123,337 | 0 | ||
| 2026-04-01 | Foresite Capital Management VI LLC 10% owner | Other acquisition | +680,486 | 680,486 | ||
| 2026-04-01 | Tananbaum James B. Director | Other disposition | −1,176,470 | 0 | ||
| 2026-04-01 | Tananbaum James B. Director | Other acquisition | +1,123,337 | 1,123,337 | ||
| 2026-04-01 | Tananbaum James B. Director | Other disposition | −1,123,337 | 0 | ||
| 2026-04-01 | Tananbaum James B. Director | Other acquisition | +680,486 | 680,486 | ||
| 2026-01-26 | Pangali Sanam Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +186,200 | 186,200 | ||
| 2026-01-26 | Bradley Mark Christopher Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +190,225 | 190,225 | ||
| 2026-01-26 | Drappa Jorn Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +221,450 | 221,450 | ||
| 2026-01-26 | Goldstein David M Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +216,675 | 216,675 | ||
| 2026-01-26 | Schroer John R. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +202,225 | 202,225 | ||
| 2026-01-26 | Hardiman Roy C. Chief Business & Strategy Ofcr | Grant or award · Stock Option (Right to Buy) | +190,875 | 190,875 | ||
| 2026-01-26 | Babler Martin President, CEO and Chairman | Grant or award · Stock Option (Right to Buy) | +745,875 | 745,875 | ||
| 2026-01-09 | AKKARAJU SRINIVAS Director | Purchase | +588,235 | $17.00 | $10.0M | 1,853,488 |
| 2026-01-08 | Foresite Labs, LLC 10% owner | Purchase | +117,647 | $17.00 | $2.0M | 5,702,536 |
| 2026-01-08 | Foresite Labs, LLC 10% owner | Purchase | +294,117 | $17.00 | $5.0M | 2,908,332 |
| 2026-01-08 | Foresite Capital Management VI LLC 10% owner | Purchase | +117,647 | $17.00 | $2.0M | 5,702,536 |
| 2026-01-08 | Foresite Capital Management VI LLC 10% owner | Purchase | +294,117 | $17.00 | $5.0M | 2,908,332 |
| 2026-01-08 | Tananbaum James B. Director | Purchase | +117,647 | $17.00 | $2.0M | 5,702,536 |
Page 3 of 21 · 405 trades